IGFBP2 as an immunohistochemical marker for prostatic adenocarcinoma

Applied Immunohistochemistry and Molecular Morphology

Volumn 19, Issue 4, 2011, Pages 318-328

  Ambrosini Spaltro, Andrea ^a   Farnedi, Anna ^a   Montironi, Rodolfo ^b   Foschini, Maria P ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

methylacyl CoA racemase; insulin like growth factor binding proteins; prostate cancer

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; SOMATOMEDIN BINDING PROTEIN 2;

ABLATION THERAPY; ADULT; AGED; ANDROGEN THERAPY; ARTICLE; BLADDER NECK STENOSIS; CLINICAL ARTICLE; CLINICAL FEATURE; EPITHELIUM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; TUMOR BIOPSY;

ADENOCARCINOMA; BIOPSY; EPITHELIUM; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; MALE; PROSTATE; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79959322549     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3128052936     Document Type: Article

References (32)

1. Flyvbjerg A, Mogensen O, Mogensen B, et al. Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor. J Clin Endocrinol Metab. 1997;82:2308-2313. (Pubitemid 27287605)
2. el Atiq F, Garrouste F, Remacle-Bonnet M, et al. Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer. Int J Cancer. 1994;57:491-497.
3. Ranke MB, Maier KP, Schweizer R, et al. Pilot study of elevated levels of insulin-like growth factor-binding protein-2 as indicators of hepatocellular carcinoma. Horm Res. 2003;60:174-180. (Pubitemid 37256063)
4. Russo VC, Schutt BS, Andaloro E, et al. Insulin-like growth factor binding protein-2 binding to extracellular matrix plays a critical role in neuroblastoma cell proliferation, migration, and invasion. Endocrinology. 2005;146:4445-4455. (Pubitemid 41324043)
5. Marucci G, Morandi L, Magrini E, et al. Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20. Virchows Arch. 2008;453:599-609.
6. So AI, Levitt RJ, Eigl B, et al. Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clin Cancer Res. 2008;14:6944-6954.
7. Park KH, Gad E, Goodell V, et al. Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer. Cancer Res. 2008;68:8400-8409.
8. Espelund U, Cold S, Frystyk J, et al. Elevated free IGF2 levels in localized, early-stage breast cancer in women. Eur J Endocrinol. 2008;159:595-601.
9. Chaib H, Cockrell EK, Rubin MA, et al. Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis. Neoplasia. 2001;3:43-52. (Pubitemid 32201609)
10. Bubendorf L, Kolmer M, Kononen J, et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst. 1999;91:1758-1764. (Pubitemid 29518772)
11. Kiyama S, Morrison K, Zellweger T, et al. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res. 2003;63:3575-3584. (Pubitemid 36793038)
12. Richardsen E, Ukkonen T, Bjornsen T, et al. Overexpression of IGBFB2 is a marker for malignant transformation in prostate epithelium. Virchows Arch. 2003;442:329-335. (Pubitemid 36561089)
13. Tennant MK, Thrasher JB, Twomey PA, et al. Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. J Clin Endocrinol Metab. 1996;81:411-420. (Pubitemid 26035052)
14. Thrasher JB, Tennant MK, Twomey PA, et al. Immunohistochemical localization of insulin-like growth factor binding proteins 2 and 3 in prostate tissue: clinical correlations. J Urol. 1996;155:999-1003. (Pubitemid 26052697)
15. Inman BA, Harel F, Audet JF, et al. Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival. Eur Urol. 2005;47:695-702. (Pubitemid 40521924)
16. Ho PJ, Baxter RC. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endocrinol (Oxf). 1997;46:333-342. (Pubitemid 27174339)
17. Cohen P, Peehl DM, Stamey TA, et al. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab. 1993;76:1031-1035. (Pubitemid 23110857)
18. Kanety H, Madjar Y, Dagan Y, et al. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab. 1993;77:229-233. (Pubitemid 23206808)
19. Yu H, Nicar MR, Shi R, et al. Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence. Urology. 2001;57:471-475. (Pubitemid 32194420)
20. Roddam AW, Allen NE, Appleby P, et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med. 2008;149:461-468.
21. Rowlands MA, Gunnell D, Harris R, et al. Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer. 2009;124:2416-2429.
22. Jiang Z, Wu CL, Woda BA, et al. P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy. Am J Surg Pathol. 2002;26:1169-1174. (Pubitemid 34969186)
23. Beach R, Gown AM, Peralta-Venturina MN, et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol. 2002;26:1588-1596. (Pubitemid 35387221)
24. Edge S, Byrd D, Compton C, et al. AJCC Cancer Staging Manual. New York: Springer; 2010:457-468.
25. Epstein JI, Allsbrook WC Jr, Amin MB, et al. The 2005 International society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29:1228-1242.
26. McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109:716-721.
27. Figueroa JA, De Raad S, Tadlock L, et al. Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer. J Urol. 1998;159:1379-1383. (Pubitemid 28172839)
28. Degraff DJ, Aguiar AA, Sikes RA. Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions. Am J Transl Res. 2009;1:115-130.
29. Moore MG, Wetterau LA, Francis MJ, et al. Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells. Int J Cancer. 2003;105:14-19. (Pubitemid 36418479)
30. Burchardt T, Burchardt M, Chen MW, et al. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol. 1999;162:1800-1805. (Pubitemid 29474732)
31. Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma. Prostate. 1999;39:135-148.
32. Mazzucchelli R, Morichetti D, Lopez-Beltran A, et al. Neuroendocrine tumours of the urinary system and male genital organs: clinical significance. BJU Int. 2009;103:1464-1470.